Increased risk of cardiovascular events with parecoxib/valdecoxib : a systematic review and meta-analysis

Determines the risk of serious cardiovascular events associated with the use of the COX-2 inhibitor valdecoxib and its prodrug parecoxib following major surgery. Performs a systematic review and meta-analysis of placebo-controlled randomised double-blind clinical trials of IV parecoxib followed by oral valdecoxib treatment, that presented data on serious cardiovascular events. Calculates the pooled fixed-effects estimates for the odds ratio for risk of cardiovascular events for the use of parecoxib/valdecoxib. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.